In a subgroup analysis, we evaluated whether the extent of perfusion deficit influences FLAIR lesion visibility and thus plays a role as a confounding variable in the interpretation of FLAIR images. A

subgroup of patients from a previous study evaluating the use of FLAIR imaging as a surrogate marker of lesion age within the first 6 hours of ischemic stroke were examined to determine the influence of the amount of perfusion deficit on FLAIR lesion visibility. N= 48 patients were included into the analysis. In positive and negative FLAIR lesion cases the extent of perfusion deficits did not differ significantly (150 mL vs. 197 mL, P= .730) nor influenced FLAIR visibility independently. In contrast, diffusion weighted imaging (DWI) lesion volumes were larger (34 mL vs. 14 mL, P= .008) and time from symptom onset longer (180 vs. 120 minute, P= .071) in FLAIR-positive cases. Visibility Silmitasertib ic50 of FLAIR lesions in acute stroke imaging is influenced by lesion size and time from symptom onset to MRI, but not by the amount of perfusion deficit calculated by time-to-peak (TTP) measurements. “
“To evaluate the variability of determining eligibility for intravenous thrombolysis (IV t-PA) by a stroke team interpretation of computed tomographic (CT) scan Romidepsin solubility dmso of the head versus

review of the radiology interpretation (presented in final report) in patients with acute ischemic stroke. We compiled a database of all IV t-PA-treated ischemic stroke patients at our academic institution based on the stroke team’s CT scan interpretation. The CT scan reports of 171 patients were reviewed by an independent board-certified vascular neurologist who was blinded to clinical information except that all patients were being

considered for IV t-PA to determine their eligibility for thrombolysis. The reviewer’s responses were then compared with the treating team’s decision to identify discrepancies, and the impact of the discrepant decisions on clinical outcome including 24-hour National Institute of Health stroke Scale (NIHSS) score and discharge modified Rankin scale (mRS), symptomatic hemorrhage selleck compound (sICH), and asymptomatic hemorrhage (aICH). We compared the outcomes of patients who received IV t-PA despite cautionary neuroradiologist interpretation and placebo-treated patients from NINDS t-PA study. The independent reviewer decided to treat with IV t-PA 123 patients (72%) after reviewing the radiology reports. The rate of NIHSS score improvement (52.0% vs. 62.5%, P = .22) was not different between patients in whom IV t-PA should or should not have been used based on radiology reports. Favorable clinical outcome defined by mRS of 0-2 at discharge (50.4% vs. 47.9%, P = .77) and in-hospital mortality (15.6% vs. 12.5%, P = .61) were similar between the 2 groups.